8 Best Small-Cap Growth Stocks to Buy According to Analysts

5. Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Market Capitalization: $1.85 Billion

Number of Hedge Fund Holders: 29

Analyst Upside Potential: 61.10%

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a biopharmaceutical company that focuses on creating new medicines for people with serious and rare diseases, particularly Thyroid Eye Disease (TED). TED is a condition that can cause symptoms like bulging eyes and vision problems. The company is conducting two major clinical trials (called THRIVE and THRIVE-2) to test a treatment named VRDN-001. They have also been working on another treatment called VRDN-003, which can be administered as a subcutaneous injection.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) on September 10, announced positive results for its Phase 3 THRIVE clinical trial for Veligrotug. The results showed that after a week 70% of patients treated with Veligrotug showed improvement in bulging eyes compared to only 5% in the placebo group, thereby indicating strong efficiency. The company plans to submit a Biologics License Application (BLA) for Veligrotug in the second half of 2025.

Financially, the company reported cash, cash equivalents, and short-term investments were $571.4 million as of June 30. Management believes that this liquidity is enough to keep the company functioning till at least the second half of 2026. It is one of the best small-cap growth stocks to buy according to analysts.